TQB2450 + anlotinib + pemetrexed

**TQB2450 + anlotinib + pemetrexed** is a combination therapy used in clinical trials for advanced or metastatic non-small cell lung cancer (NSCLC). - **TQB2450 (benmelstobart)** is a humanized IgG1 monoclonal antibody targeting programmed cell death ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80, thereby activating T-cell mediated immune responses against tumor cells[1][3]. - **Anlotinib** is a small molecule multi-targeted tyrosine kinase inhibitor, predominantly inhibiting VEGF receptors, fibroblast growth factor receptors (FGFRs), PDGF receptors, c-Kit, and Ret to block angiogenesis and tumor proliferation[3]. - **Pemetrexed** is an antifolate antineoplastic agent (chemotherapeutic) inhibiting the folate-dependent enzymes involved in nucleotide synthesis, leading to inhibition of DNA and RNA synthesis, primarily targeting rapidly dividing cancer cells[2][4][10]. This combination has demonstrated clinical benefit, notably improving progression-free survival and overall survival in NSCLC patients in phase III trials, by integrating immune checkpoint inhibition, anti-angiogenesis, and cytotoxic chemotherapy[1][3][5].

Other names

TQB2450TQB-2450TQB 2450benmelstobartanlotinib hydrochloridepemetrexed disodiumAlimtaPemfexyPemrydi RTU